TABLE 1.
Characteristics of participants at baseline
| Baseline demographics | Placebo (N = 86) | 10 mg LY3154207 (N = 86) | 30 mg LY3154207 (N = 85) | 75 mg LY3154207 (N = 87) | Overall (N = 344) |
|---|---|---|---|---|---|
| Male, % | 81.4 | 84.9 | 82.4 | 82.8 | 82.8 |
| Age, mean | 73.1 | 72.5 | 71.9 | 73.0 | 72.6 |
| White, % | 91.9 | 94.2 | 95.3 | 97.7 | 94.8 |
| AChEI use, % | 44.2 | 39.5 | 44.7 | 41.4 | 42.4 |
| DLB, % | 50.6 | 38.1 | 36.6 | 26.2 | 37.8* |
| PDD, % | 49.4 | 61.9 | 63.4 | 73.8 | 62.2* |
| Concomitant PD therapy use, % | 83.7 | 86.0 | 83.5 | 89.7 | 85.8 |
| LEDD (mg), mean | 621.2 | 610.1 | 606.9 | 677.8 | 629.5 |
|
MoCA Total score, % |
|||||
| Mild 17 , 18 , 19 , 20 , 21 , 22 , 23 | 68.6 | 69.8 | 80.0 | 69.0 | 71.8 |
| Moderate 10 , 11 , 12 , 13 , 14 , 15 , 16 | 31.4 | 30.2 | 20.0 | 31.0 | 28.2 |
| Clinical characteristics, mean (SD) | |||||
| CDR‐CoA | 28.15 (7.23) | 28.84 (7.50) | 28.81 (12.15) | 28.98 (6.19) | 28.70 (8.53) |
| ADAS‐cog13 | 27.52 (8.67) | 27.77 (11.22) | 25.07 (9.42) | 26.24 (10.32) | 26.65 (9.97) |
| MDS‐UPDRS | |||||
| Total | 61.77 (24.57) | 63.33 (25.19) | 64.10 (24.15) | 69.44 (23.47) | 64.70 (24.41) |
| Part I | 12.45 (6.04) | 13.03 (6.32) | 13.06 (6.34) | 13.00 (4.84) | 12.89 (5.89) |
| Part II | 15.92 (9.12) | 14.66 (8.39) | 15.26 (8.05) | 16.78 (7.96) | 15.66 (8.39) |
| Part III | 33.14 (14.68) | 35.85 (15.72) | 35.58 (14.71) | 39.35 (15.11) | 36.02 (15.16) |
| ESS | 10.88 (5.68) | 9.53 (4.82) | 9.32 (4.91) | 10.17 (5.83) | 9.98 (5.35) |
| MoCA total | 18.02 (3.54) | 18.19 (3.21) | 18.80 (3.00) | 17.89 (3.85) | 18.22 (3.42) |
| Modified H&Y | 2.53 (0.75) | 2.42 (0.67) | 2.51 (0.67) | 2.56 (0.80) | 2.51 (0.72) |
*
P < 0.05.
Abbreviations: N, number of participants; AChEI, acetylcholinesterase inhibitor; DLB, dementia with Lewy bodies; PDD, Parkinson's disease dementia; PD, Parkinson disease; LEDD, levodopa equivalent daily dose; MoCA, Montreal Cognitive Assessment; SD, standard deviation; CDR‐CoA, Cognitive Drug Research‐Continuity of Attention composite score; ADAS‐cog13, Alzheimer's Disease Assessment Scale‐Cognitive Subscale 13; MDS‐UPDRS, Movement Disorder Society‐Unified Parkinson Disease Rating Scale; ESS, Epworth Sleepiness Scale; H&Y, Hoehn and Yahr.